Skip to main content
SpringerLink
Log in

On the Management of Metastatic Prostate Cancer with LH-RH Analogs

  • Chapter
Peptides in Oncology I

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 124))

Abstract

With the availability of luteinizing hormone releasing hormone (LH-RH) agonists, and in the future of maybe also of LH-RH antagonists, new principles were introduced into the clinical management of human prostate carcinoma and other steroid-hormone-dependent tumors (Schröder et al. 1987). LH-RH agonists offered a new principle of suppressing testicular androgen to castration levels, the major advantage of which over the classical forms of treatment with estrogen administration or castration seemed to be an absence of physical side effects and a reduction of physiological side effects. For these advantages a much higher price has to be paid, and it now remains questionable in how far LH-RH agonists will be able to compete with other principles of castration in the management of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alcini E, D’Addessi A, Destito A, Grasso G (1988) LH-RH analogue treatment for advanced prostate cancer. Am J Clin Oncol 11 [Suppl 2]:S120–S122

    Article  PubMed  Google Scholar 

  • Blom JHM, Hirdes WH, Schröder FH, De Jong FH, Kwekkeboom DJ, van Veen AJ, Sandow J, Krauss B (1989) Pharmacokinetics and endocrine effects of the LHRH analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol Res 17:43–46

    Article  PubMed  CAS  Google Scholar 

  • Brisset J-M, Boccon-Gibod L, Botto H, Camey M, Cariou G, Duclos J-M, Duval F, Gonties D, Jorest R, Lamy L, LeDuc A, Mouton A, Petit M, Prawerman A, Richard F, Sava-tovsky I, Vallancie G (1987) Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. In: Khoury S, Murphy GP (eds) Cancer of the prostate. Liss, New York

    Google Scholar 

  • Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424

    Article  PubMed  CAS  Google Scholar 

  • Debruyne F (1989) Luteinizing hormone-releasing hormone analogues alone in the treatment of advanced disease. Horm Res 32 [Suppl 1]: 62–65

    Article  PubMed  Google Scholar 

  • Debruyne FMJ, Denis L, Lunglmayr G, Mahler C, Newling DWW, Richards B, Robinson MRG, Smith PH, Weil EHJ, Whelan P (1988) Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 140:775–777

    PubMed  CAS  Google Scholar 

  • Denis L (1989) LHRH analogues in combination with an anti-androgen in the treatment of advanced disease. Horm Res 32 [Suppl 1]:66–68

    Article  PubMed  Google Scholar 

  • Denis L, Keuppens F, Robinson M, Mahler C, Smith P, Pinto de Carvalho APA, Newling D, Bono A, Sylvester R, De Pauw M, Vermeylen K, Ongena P and members of the EORTC GU group (1990) Complete androgen blockade: data from an EORTC 30853 trial. Sem Urol 8:166–174

    CAS  Google Scholar 

  • Decensi AU, Guarneri D, Marroni P, Cristina L, Paganuzzi M, Boccardo F (1989) Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men. J Urol 142:1235–1238

    PubMed  CAS  Google Scholar 

  • De Sy WA, De Meyer JM, Casselman J, De Smet R, Renders G, Schelfhout W, De Wilde P (1986) A comparative study of a long acting luteinizing hormone releasing hormone agonist (decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Acta Urol Belg 54:221–229

    PubMed  Google Scholar 

  • Grant JBF, Ahmed SR, Shake SM, Costello CB, Howell A, Blacklock NJ (1986) Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. Br J Urol 58:539–544

    Article  PubMed  CAS  Google Scholar 

  • Habenicht UF, Witthaus E, Neumann F (1986) Antiandrogens and LH-RH agonists endocrinology in the initial phase of their use. Akt Urol 17:10–16

    Article  Google Scholar 

  • Iversen P, Christensen MG, Friis E, Hornbol P, Hvidt V, Iversen HG, Klarskov P, Kramp T, Lund F, Mogensen P, Pedersen T, Rasmussen F, Rose C, Skaarup P, Wolf H (1990) A phase III trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66:1058–1066

    PubMed  CAS  Google Scholar 

  • Jones WG, Fossá SD, Bono A, Croies JJ, Stoter G, De Pauw M, Sylvester R, members of the EORTC Gentourinary Tract Cancer Cooperative Group (1986) Mitimycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. World J Urol 4:182–185

    Article  Google Scholar 

  • Kotake T, Usami M, Sonoda T, Matsuda M, Okajima E, Osafune M, Isurugi K, Akaza H, Saitoh Y (1988) LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S1O8–S111

    Article  Google Scholar 

  • Koutsilieris M, Faure N, Tolis G, Laroche B, Robert G, Ackman CFD (1986) Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either buserelin or orchiectomy. Urology 27:221–228

    Article  PubMed  CAS  Google Scholar 

  • Kuhn J-M, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis J-F, Costa P, Husson J-M, Dahan R, Bertagna C, Edelstein R (1989) Prevention of the transient edverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321:413–418

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Dupont A, Belanger A, Lacoursiere Y, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4:579–594

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Dupont A, Belanger A (1985) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23:833–841

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguere M, Lacoursiere Y, Emond J, Monfette G (1986) Treatment of prostate cancer with gonadotropin-relasing hormone agonists. Endocr Rev 7:67–74

    Article  PubMed  CAS  Google Scholar 

  • Leuprolide Study Group (1984) Leuprolide versus Diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281–1286

    Article  Google Scholar 

  • Mahler C, Denis L (1988) Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S127–S128

    Article  PubMed  Google Scholar 

  • Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner T, Drago J (1986) Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial. Anticancer Res 6:309–314

    PubMed  CAS  Google Scholar 

  • Mauriac L, Coste P, Richaud P, Lamarche P, Mage P, Bonichon F (1988) Clinical study of an LH-RH agonist (ICI 118630, Zoladex) in the treatment of prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S117–S119

    Article  PubMed  Google Scholar 

  • Metz R, Namer M, Adenis L, Audhuy B, Bugat R, Colombel P, Couette JE, Grise P, Khater R, LePorz B, Levin G, Marti P, Mauriac M, Rouxel A, Tetelboum R (1988) Zoladex as primary therapy in advanced prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S112–S114

    Article  PubMed  Google Scholar 

  • Navratil H (1987) Double-blind study of Anandron versus placebo in Stage D2 prostate cancer patients receiving buserelin. Results in 49 cases from a multicentre study. In: Khoury S, Murphy GP (eds) Cancer of the prostate. Liss, New York

    Google Scholar 

  • Neri R, Florance K, Koziol P, Van Cleave S (1972) A biological profile of a nonsteroidal antiandrogen, Sch 13521 (4′-nitro-3′-trifluoromethylisobutyranalide). Endocrinology 91:427–437

    Article  PubMed  CAS  Google Scholar 

  • Oesterling JE, Epstein JI, Walsh PC (1986) The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypog-onadism and panhypopituitarism. J Urol 136:1030–1034

    PubMed  CAS  Google Scholar 

  • Parmar H, Lightman SL, Allen L, Phillips RH, Edwards L, Schally AV (1985) Randomised controlled study of orchiectomy vs long-acting D-Trp6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 30:1201–1205

    Article  Google Scholar 

  • Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL (1987) Orchiectomy versus long-acting D-Trp6-LHRH in advanced prostatic cancer. Br J Urol 59:248–254

    Article  PubMed  CAS  Google Scholar 

  • Petersson F, Hammar M, Mathson K, Hjertberg H, Varenhorst E (1987) Influence of continuous luteinizing hormone-releasing hormone agonist on steroidogenic enzymes in the human testis. Scand J Urol Nephrol 21:267–271

    Article  PubMed  CAS  Google Scholar 

  • Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone actetate and megestrol acetate. Mol Cell Endocrinol 42:283–288

    Article  PubMed  CAS  Google Scholar 

  • Robinson MRG, Hetherington J (1986) The EORTC studies: is there an optimal endocrine management for Ml prostatic cancer? World J Urol 4:171–175

    Article  Google Scholar 

  • Roger M, Duchier J, Lahlou N, Nahoul K, Schally AV (1985) Treatment of prostatic carcinoma with D-Trp6-LH-RH: plasma hormone levels after daily subcutaneous injections and periodic administration of delayed-release preparations. Prostate 7:271–282

    Article  Google Scholar 

  • Sandow J, Beier B (1985) LHRH agonists: mechanism of action and effect on target tissues. Prog Clin Biol Res 185A:121–142

    PubMed  CAS  Google Scholar 

  • Schröder FH, Lock TMTW, Chadha DR, Debruyne FMJ, Karthaus HFM, De Jong FH, Klijn JGM, Matroos AW, De Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acatate. J Urol 137:912–918

    Google Scholar 

  • Schulze H, Senge T (1990) Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carinoma of the prostate. J Urol 144:934–941

    PubMed  CAS  Google Scholar 

  • Schulze H, Isaacs J, Senge T (1987) Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. J Urol 137:909–911

    PubMed  CAS  Google Scholar 

  • Sharifi R, Soloway M, The Leuprolide Study Group (1990) Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 143:68–71

    PubMed  CAS  Google Scholar 

  • Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD (1973) Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45:668–677

    Article  PubMed  CAS  Google Scholar 

  • Thompson IM, Zeidman EJ, Rodriguez FR (1990) Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 144:1479–1480

    PubMed  CAS  Google Scholar 

  • Waxman JH, Sandow J, Man A, Barnett MJ, Hendry WF, Besser GM, Oliver RTD, Magill PJ (1986) The first clinical use of depot buserelin for advanced prostatic carcinoma. Cancer Chemother Pharmacol 18:174–175

    Article  PubMed  CAS  Google Scholar 

  • Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O’Donoghue EPN, Sikora K (1988) The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-re-leasing hormone analogue. Am J Clin Oncol 11 [Suppl 2]:S152–S155

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Erasmus University, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands

    J. H. M. Blom & F. H. Schröder

Authors
  1. J. H. M. Blom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. H. Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, W-4300, Essen, Germany

    K. Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Blom, J.H.M., Schröder, F.H. (1992). On the Management of Metastatic Prostate Cancer with LH-RH Analogs. In: Höffken, K. (eds) Peptides in Oncology I. Recent Results in Cancer Research, vol 124. Springer, Milano. https://doi.org/10.1007/978-88-470-2186-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2186-0_4

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2188-4

  • Online ISBN: 978-88-470-2186-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation